| 摘要 |
The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT3 receptor antagonist ondansetron and a selective dopamine D2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subject's obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.
|
